Beam Therapeutics Inc. (BEAM)

Name: Beam Therapeutics Inc. (BEAM) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001745999 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Beam Therapeutics Inc. reported revenue of $139.74M. Revenue grew 120.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $156.03M.

Key ratios (year ended 2025-12-31)

-274.6%

Operating margin

-57.2%

Net margin

-6.5%

Return on year-end equity

120.0%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-16

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Revenue	$156.03M	$139.74M	$63.52M	$377.71M	$60.92M	$51.84M	$24.0K	$18.0K
R&D Expense	$408.66M	$409.62M	$367.56M	$437.38M	$311.59M	$387.09M	$103.18M	$54.62M
Operating Income	-$378.02M	-$383.69M	-$415.57M	-$176.49M	-$338.48M	-$392.46M	-$132.76M	-$75.15M
Depreciation & Amortization	$22.24M	$22.29M	$21.93M	$20.01M	$14.15M	$7.45M	$4.74M	$3.50M
EBITDA	-$355.78M	-$361.40M	-$393.64M	-$156.47M	-$324.33M	-$385.01M	-$128.03M	-$71.65M
Net Income	n/a	-$79.99M	-$376.74M	-$132.53M	-$289.09M	-$370.64M	-$194.59M	-$78.33M
EPS (Diluted)	n/a	-$0.81	-$4.58	-$1.72	-$4.13	-$5.77	-$4.19	-$14.05
Total Assets	$1.39B	$1.48B	$1.10B	$1.46B	$1.34B	$1.47B	$451.68M	$156.10M
Total Liabilities	$318.91M	$242.82M	$370.28M	$478.38M	$608.24M	$647.72M	$206.12M	$55.15M
Shareholders' Equity	$1.07B	$1.24B	$733.54M	$981.33M	$733.47M	$826.74M	$245.56M	-$201.10M
Cash & Equivalents	$219.82M	$294.94M	$281.97M	$435.89M	$232.77M	$559.99M	$162.17M	$37.22M
Operating Cash Flow	-$359.38M	-$345.10M	-$347.25M	-$149.19M	$22.53M	-$66.27M	-$95.74M	-$72.00M
Capital Expenditures	$13.39M	$14.95M	$8.95M	$33.73M	$48.95M	$46.81M	$16.36M	$12.52M
Free Cash Flow	-$372.77M	-$360.05M	-$356.19M	-$182.93M	-$26.42M	-$113.08M	-$112.10M	-$84.52M
Shares Outstanding	103.26M	101.75M	83.63M	81.63M	71.28M	68.39M	57.25M	7.33M
Weighted Average Diluted Shares	n/a	98.91M	82.31M	77.15M	70.02M	64.23M	46.73M	6.48M
EPS (Basic)	n/a	-$0.81	-$4.58	-$1.72	-$4.13	-$5.77	-$4.19	-$14.05

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView